<DOC>
	<DOCNO>NCT00616564</DOCNO>
	<brief_summary>High-dose IL-2 treatment metastatic melanoma approve FDA 1998 . Studies GM-CSF plus IL-2 address approve dose schedule . This protocol study combination HD-IL2 GM-CSF give potential synergistic interaction discuss .</brief_summary>
	<brief_title>Phase II Trial ( IL-2 ) With Priming ( GM-CSF ) Patients With Advanced Melanoma</brief_title>
	<detailed_description>The primary objective phase II multicenter trial : Determine 1 2-year survival patient treat accord protocol . Assess safety toxicity regimen patient population . The secondary objective : Determine freedom progression ( FFP ) . Measure response rate ( RR ) . Obtain immunological data use regimen vivo ( separate project : Moffitt ? ) . The propose study multicenter phase II trial HD-IL-2 combination GM-CSF . GM-CSF start 7 day day 1 HD-IL-2 continue 4 week day 28 , encompass two cycle HD-IL2 . The first 9 patient closely monitor unexpected toxicity .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm diagnosis melanoma measurable disease Patients stage IV unresectable advance melanoma Age least 16 year . ECOG performance status 01 Life expectancy &gt; 3 month Adequate major organ function tolerate therapy , define : Total bilirubin 2.0 mg/dL . Creatinine 1.8 mg/dL . WBC 3,000/mm3 . Platelet count 100,000/mm3 . Patients 50 year age one cardiac risk factor must demonstrate normal exercise stress test , stress thallium test , comparable cardiac ischemia evaluation Left ventricular ejection fraction &gt; 40 % Women childbearing age must agree use barrier method birth control demonstrate negative pregnancy test prior initiation protocol therapy . Periodic negative urine pregnancy test also require . Patients must give write informed consent No prior HD IL2 stage IV/unresectable advance disease . Prior low dose IL2 allow . No 2 prior chemotherapy regimen allow . No active CNS metastasis . Treated CNS metastasis without recurrence progression &gt; 8 week allow . No concurrent use systemic corticosteroid Pregnant and/or lactate exclude No concurrent antineoplastic treatment , include chemotherapy , biologic response modifier , radiation , vaccine , experimental therapy . No treatment melanoma within previous 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>GM-CSF</keyword>
	<keyword>Interleukin</keyword>
	<keyword>IL-2</keyword>
	<keyword>Sargrostim</keyword>
</DOC>